Zelira Therapeutics Share Price and Company Fundamentals



Price
$1.6
Change
-0.150 (-8.571%)
52 week
0.9 - 8.750437

Last traded: Yesterday at 5:25 AM

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; the Children's Hospital of Philadelphia (CHOP) on opioid reduction study; HAPA Pharm BV; and Ethicann. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was founded in 2003 and is headquartered in Perth, Australia.

Key Metrics

PE ratio

-

PB ratio

0.42

Dividend yield

0.00%

Beta

1.68

Market cap

-

Enterprise value

-

Company profile

Primary activitiesBio-pharmaceutical
Industry / SectorBiotechnology / Healthcare
Websitehttps://www.zeliratx.com
Mailing address101 St Georges Terrace Level 3 Perth WA 6000 Australia
Phone / Fax61 8 6558 0886 / 61 8 6316 3337
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Annual reports

Published onReport
30 Sep 2021Annual Report to shareholders

Dividends

More: Zelira Therapeutics Dividend history, yield and payout ratio

Dividend yield

0.00%

Dividend amount

$0.00

Payout ratio

0.00%

Zelira Therapeutics paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.ZLD dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.

ZLD's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of Aug 2022, following are the company executives and directors listed on Zelira Therapeutics.

NameTitleAgeTotal Pay
Mr. Osagie O. Imasogie Esq.Founder & Chairman59144k
Dr. Oludare OdumosuMD, Global CEO & Director371.73k
Mr. Rahul GanesanVP of Fin. & Accounting
Mr. Greg BlakeVP of Global and Head of Commercial & Partnering
Mr. Timothy Ryan SlateNon-Exec. Director & Company Sec.
Dr. Patty WasherClinical Trial Consultant

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-752.17%

Return on assets

-14.44%

Return on equity

-25.71%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Zelira Therapeutics is and its enterprise value is .

The ZLD's stocks Beta value is 1.68 making it 68% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Zelira Therapeutics (ZLD)

Zelira Therapeutics (ASX:ZLD) Frequently Asked Questions

1. What is Zelira Therapeutics's Stock Symbol?

Zelira Therapeutics trades on ASX under the ticker symbol "ZLD".

2. What is Zelira Therapeutics's stock price today?

One share of ZLD stock can currently be purchased for approximately $1.6.

3. How can I contact Zelira Therapeutics?

Zelira Therapeutics's mailing address is 101 St Georges Terrace Level 3 Perth WA 6000 Australia. The company can be reached via phone at 61 8 6558 0886.

4. What is Zelira Therapeutics's official website?

The official website of Zelira Therapeutics is https://www.zeliratx.com.

5. Which share registry manages Zelira Therapeutics's stock?

Zelira Therapeutics's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.